Verzenio

Showing 6 posts of 6 posts found.

lilly_entrance_web

Lilly’s Verzenio combo shows additional breast cancer survival benefit in new Phase 3 data

July 31, 2019
Research and Development Cancer, Eli Lilly, Verzenio, breast cancer, pharma

Eli Lilly has revealed new Phase 3 data on its CDK4 & 6 inhibitor Verzenio (abemaciclib), demonstrating its efficacy in …

lilly_entrance_web

Japan’s health ministry warns of serious side effects of Lilly’s Verzenio

May 23, 2019
Business Services, Medical Communications Cancer, Eli Lilly, Verzenio, breast cancer, oncology, pharma

Japan’s Health Ministry has warned that Eli Lilly’s breast cancer therapy Verzenio could have serious side effects for patient’s lungs. …

Lilly’s Verzenio gets first-line EU approval for HER2- advanced breast cancer

October 3, 2018
Research and Development, Sales and Marketing Cancer, Eli Lilly, Verzenio, breast cancer, pharma

The European Medicines Agency has confirmed its approval of Eli Lilly’s CDK4/6 inhibitor Verzenio (ademaciclib), it has emerged. The therapy …

FDA expands indication of Lilly’s Verzenio in advanced breast cancer

February 27, 2018
Manufacturing and Production, Sales and Marketing Cancer, Eli Lilly, FDA, Verzenio, breast cancer, pharma

Eli Lilly is celebrating the news that its cyclin-dependent kinase (CDK) 4 & 6 inhibitor Verzenio (ademaciclib) has received approval …

lilly2_web

Lilly receives FDA breast cancer pill approval, doubts remain

September 29, 2017
Medical Communications, Sales and Marketing Eli Lilly, Verzenio, biotech, drugs, pharma, pharmaceutical

Eli Lilly has received an important approval for its breast cancer treatment, Verzenio. The drug will be the third to …

Latest content